(firstQuint)Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC).

 This is a phase 1/2 clinical trial of the oral XPO1 inhibitor selinexor (KPT-330) in combination with docetaxel for previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).

 It is a single-arm, non-blinded study, which will compare safety and outcomes with historical controls (docetaxel monotherapy).

 The multi-center study will be conducted within the Academic Thoracic Oncology Medical Investigator Consortium (ATOMIC).

.

 Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)@highlight

This study is being done to evaluate the safety of the investigational study drug, selinexor when given with docetaxel to patients who have been previously treated for advanced KRAS mutant lung cancer.

